Small nucleolar RNAs (snoRNAs) are conserved noncoding RNAs best studied as ribonucleoprotein (RNP) guides in RNA modification 1,2 . To explore their role in cancer, we compared 5,473 tumor-normal genome pairs to identify snoRNAs with frequent copy number loss. The SNORD50A-SNORD50B snoRNA locus was deleted in 10-40% of 12 common cancers, where its loss was associated with reduced survival. A human protein microarray screen identified direct SNORD50A and SNORD50B RNA binding to K-Ras. Loss of SNORD50A and SNORD50B increased the amount of GTP-bound, active K-Ras and hyperactivated Ras-ERK1/ERK2 signaling. Loss of these snoRNAs also increased binding by farnesyltransferase to K-Ras and increased K-Ras prenylation, suggesting that KRAS mutation might synergize with SNORD50A and SNORD50B loss in cancer. In agreement with this hypothesis, CRISPRmediated deletion of SNORD50A and SNORD50B in KRASmutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types. SNORD50A and SNORD50B snoRNAs thus directly bind and inhibit K-Ras and are recurrently deleted in human cancer.
types (Fig. 1b,c) , as determined using conservative CNA thresholds ( Supplementary Fig. 1a-c) . By comparison, publicly available TCGA analysis with the GISTIC algorithm places the overall incidence of SNORD50A/B deletion across all tumor types at 24.9%, with SNORD50A/B in significant deletion peaks. Our analysis observed somatic SNORD50A/B deletions in at least 20% of melanomas as well as ovarian, liver, lung and breast tissue malignancies, suggesting a role for SNORD50A and SNORD50B loss in cancer.
Consistent with this hypothesis, SNORD50A/B loss was associated with decreased overall survival in the TCGA cohort of breast adenocarcinoma (Fig. 1d) . Additionally, levels of RNA transcripts from the host gene for SNORD50A and SNORD50B, SNHG5, were decreased in the multiple cancer types where its expression has been measured ( Fig. 1e-h ). Analysis of other annotated snoRNA host genes demonstrated that the downregulation observed for SNHG5 is not a general phenomenon in cancer (Supplementary Fig. 1d ). Decreases in SNHG5 expression were in some cases more profound than the incidence of genomic deletion for a given tumor, suggesting that additional mechanisms might exist to downregulate its expression in cancer. Analysis of transcription factors binding near the SNHG5 promoter was performed using Encyclopedia of DNA Elements (ENCODE) chromatin immunoprecipitation and sequencing (ChIPseq) data and TCGA melanoma RNA sequencing (RNA-seq) data, identifying HMGN5 and MYC among the transcription factors whose expression correlated most with SNHG5 expression ( Supplementary  Fig. 1e-g ). Methylation at the CpG island nearest to SNHG5 did not correlate with SNHG5 expression (Supplementary Fig. 1h ). Decreased SNHG5 expression was associated with reduced survival in both the breast cancer and cutaneous melanoma patient cohorts ( Fig. 1i and Supplementary Fig. 1i) . Therefore, the SNORD50A/B locus is commonly deleted in multiple human cancer types, and SNORD50A/B loss correlates with poorer clinical outcome.
SNORD50A and SNORD50B are co-located on chromosome 6q14.3. RNA-seq of polyadenylated RNA by the ENCODE Project did not detect a transcript spanning SNORD50A and SNORD50B, indicating that they do not function as nuclear long noncoding RNA (lncRNA) caps 12 .
l e t t e r s SNORD50A and SNORD50B encode two C/D box-containing snoRNAs that specify sites for 2′-O-ribose methylation on target RNAs, such as 28S rRNA 13 . Because such housekeeping functions do not suggest obvious links to carcinogenesis and because RNAprotein interactions are integral to snoRNA action, we undertook a screen to identify cancer-relevant proteins that bind SNORD50A and SNORD50B. We modified a recently developed approach for binding of long RNA to high-density protein microarrays of 9,125 recombinant human proteins 14, 15 to facilitate small RNA hybridization (SR-PMA) (Fig. 2a) . Hybridization of 75-nucleotide (nt) SNORD50A and 71-nt SNORD50B RNAs identified specific binding to independently spotted recombinant K-Ras4A and K-Ras4B proteins ( Fig. 2b and Supplementary Fig. 2a-e) . Although SNORD50A and SNORD50B bound K-Ras most strongly, they also bound additional GTPases (Fig. 2c, Supplementary Fig. 2c,f and Supplementary Table 1) .
In contrast, hybridization with 30 other noncoding and coding RNAs, including ten additional snoRNAs, failed to detect binding to even a single GTPase (Supplementary Fig. 2g and Supplementary Table 2 ). We confirmed SNORD50A and SNORD50B binding to K-Ras using ultraviolet light (UV) cross-linking and immunoprecipitation (CLIP), which identified K-Ras association with SNORD50A and SNORD50B but not with control C/D-box or H/ACA-box snoRNAs (Fig. 2d) . Moreover, CLIP demonstrated that other Ras isoforms also bind SNORD50A and SNORD50B ( Supplementary  Fig. 2h ). Further confirmation of this interaction was obtained by electromobility shift assay with purified recombinant K-Ras protein (Fig. 2e,f) . SNORD50A and SNORD50B therefore bind Ras superfamily GTPases.
To identify the sequences responsible for the K-Ras-snoRNA interaction, a series of KRAS and SNORD50A mutants were generated Chr. 6 2 Mb npg l e t t e r s (Supplementary Fig. 3a-d) . Deletion mutants were generated in the K-Ras nucleotide-binding region, the switch I region, the switch II region and the C-terminal region. Deletions within both switch regions did not reduce K-Ras binding to SNORD50A; however, deletions within the N-terminal nucleotide-binding region and Cterminal region reduced binding by 30% and 50%, respectively, suggesting that residues involved in SNORD50A interaction are widely distributed across K-Ras (Supplementary Fig. 3a,b) . To identify these residues, we superimposed the K-Ras crystal structure onto the SRP54-SRP complex with 7S RNA; this predicted that the positively charged surface residues-Lys5, Lys42, Arg149 and Arg161-of K-Ras might interact with RNA. Consistent with this notion, mutagenesis of these residues further reduced K-Ras binding to SNORD50A by 65% ( Supplementary Fig. 3a,b) . To map the SNORD50A nucleotide sequences required for K-Ras binding, we made short deletions within the C, C′, D and D′ boxes of SNORD50A and then assessed binding to K-Ras ( Supplementary Fig. 3c,d ).
Deletions within the C′, D and D′ boxes modestly reduced K-Ras binding; however, a 7-nt deletion within the C box largely abolished it ( Supplementary Fig. 3c,d ). Because K-Ras protein has been largely observed in extranuclear cell compartments and snoRNAs are primarily, but not exclusively, found in the nucleolus and Cajal bodies, we next examined where the SNORD50A and SNORD50B RNA interactions with K-Ras proteins occur. To do this, we modified proximity ligation analysis (PLA), which can detect protein-protein interactions in intact cells 16 , to identify RNA-protein interactions within cells (RP-PLA). Exogenously delivered, biotin-labeled SNORD50A and SNORD50B distributed to the nucleolus and other parts of the cell as expected (Supplementary Fig. 3e ) and identified SNORD50A and SNORD50B interacting with K-Ras protein outside the nucleus (Fig. 2g,h ).
The frequency of SNORD50A/B deletion in cancer and the direct binding of SNORD50A and SNORD50B to K-Ras protein raised the possibility that SNORD50A/B loss might contribute to activation of downstream K-Ras targets. To test this possibility, we first depleted SNORD50A and SNORD50B expression, using antisense npg l e t t e r s oligonucleotides (ASOs) because the small size of these snoRNAs constrained conventional RNA interference techniques. Decreased SNORD50A and SNORD50B levels were verified by both quantitative RT-PCR (qRT-PCR) and RNA blot analysis (Fig. 3a-c) , with the latter demonstrating single bands of full length, indicating that these snoRNAs are not processed to shorter snoRNA-derived RNA fragment (sdRNAs), including processed snoRNAs (psnoRNAs) 3 . Among K-Ras-activated targets is the ERK1/2 mitogen-activated protein kinase (MAPK) pathway, one of the signaling cascades most commonly upregulated in human cancers 17, 18 . Consistent with an impact on K-Ras action, SNORD50A and SNORD50B depletion led to ERK1/2 MAPK activation in both normal epithelial cells and cancer cells with intact Ras-ERK1/2-MAPK pathway genes ( Fig. 3d-g ). MAPK cascade activation was due to loss of SNORD50A/B as opposed to its host gene, SNHG5, as SNHG5 depletion showed no effects on the MAPK pathway ( Supplementary Fig. 4a-c) .
Strong activation of wild-type Ras, as well as active oncogenic Ras, reduces cell proliferation in vitro, in a process with features of oncogene-induced senescence; in epithelial cells, the resulting growth arrest can be partially rescued by CDK4 (refs. 19, 20) . Depletion of SNORD50A and SNORD50B reduced proliferation in vitro comparably to overexpression of oncogenic KRAS encoding a p.Gln61Leu substitution (Supplementary Fig. 4d-i) . Moreover, much as in oncogenic Ras-induced growth inhibition, this effect was partially rescued by CDK4 (Supplementary Fig. 4h,i) , indicating that the effects of SNORD50A and SNORD50B loss recapitulate these aspects of Ras activation.
To evaluate the consequences of SNORD50A/B loss on tumorigenesis, we undertook CRISPR-mediated gene deletion in CHL-1 melanoma cells (Fig. 3h and Supplementary Fig. 5a ); these cells retain intact and inducible Ras-MAPK pathway function. Parallel studies were performed in A549 and NCI-H23 lung cancer cells with oncogenic KRAS mutations (Supplementary Fig. 5 ). As in ASO-mediated knockdown, SNORD50A/B-deleted clones displayed increased levels of active, phosphorylated ERK1/2 in CHL-1 (Fig. 3i,j) , A549 ( Supplementary Fig. 5e,f,h,i) and NCI-H23 ( Supplementary  Fig. 5k,l,n,o) cells. This effect was not associated with signs of increased ribosomal stress, as assessed by ribosome profiling/Riboseq (Supplementary Fig. 5b,c) . SNORD50A/B deletion enhanced tumor growth in vivo in all three tumor cell types (Fig. 3k and  Supplementary Fig. 6a-c) . SNORD50A/B gene loss thus accelerates tumor growth in vivo in the context of both wild-type and oncogenic mutant KRAS.
Depletion of SNORD50A and SNORD50B increased levels of active GTP-bound K-Ras (Fig. 4a,b) . Overexpression of SNORD50A and SNORD50B in vitro acutely diminished the levels of active ERK1/2 induced by oncogenic K-Ras (Fig. 4c-f) , indicating that SNORD50A and SNORD50B oppose oncogenic signaling by K-Ras. Consistent with this hypothesis, tumor cells overexpressing SNORD50A and SNORD50B did not show long-term persistence (Supplementary Fig. 7a,b) .
For full biological activity, both wild-type and oncogenic mutant Ras family proteins require prenylation by enzymes such as the CAAX farnesyltransferase (FTase), which can place lipid moieties on npg l e t t e r s the C terminus of K-Ras. We thus next studied K-Ras farnesylation as a function of SNORD50A and SNORD50B. There are no antibodies that specifically recognize farnesylation of K-Ras; however, PLA can detect protein post-translational modifications (PTMs) by combining an antibody to a target protein with a PTM-specific antibody, thereby only showing signal when the PTM is present on the protein of interest 21 . We combined antibodies to K-Ras with those specific for the farnesyl moiety to detect K-Ras farnesylation within cells. Depletion of SNORD50A and SNORD50B quantitatively increased K-Ras farnesylation within cells without altering the signal for another K-Ras PTM, namely ubiquitination (Fig. 4g,h) . Consistent with this finding, SNORD50A/B-knockout cells displayed increased amounts of prenylated K-Ras protein (Supplementary Fig. 7c-h) . Loss of SNORD50A and SNORD50B therefore increases the levels of active, prenylated K-Ras.
To probe the basis for the enhanced K-Ras farnesylation seen with loss of SNORD50A and SNORD50B, we next asked whether SNORD50A and SNORD50B serve as endogenous inhibitors of FTase binding to K-Ras. Within cells, loss of SNORD50A and SNORD50B enhanced the interaction between K-Ras and FTase (Fig. 4g,h) . We confirmed this result using recombinant K-Ras and FTase proteins with in vitro-transcribed SNORD50A and SNORD50B. Consistent with observations in cells, SNORD50A and SNORD50B reduced binding of recombinant K-Ras protein to FTase in far western blotting (Supplementary Fig. 7i,j) , suggesting that SNORD50A and SNORD50B inhibit activating K-Ras farnesylation by impairing FTase binding to K-Ras.
These data indicate that SNORD50A/B snoRNAs are recurrently lost in cancer and that the mature snoRNAs bind and suppress the activity of the Ras oncoproteins. Loss of these snoRNAs enhances K-Ras association with FTase as well as causing hyperactivation of the downstream ERK1/2 MAPK pathway. Increased tumorigenesis occurs with combined oncogenic KRAS mutation and SNORD50A/B deletion, suggesting that frequent SNORD50A/B deletion might cooperate with oncogenic KRAS mutations in cancer to drive Ras-MAPK hyperactivation. Consistent with this hypothesis, we observed that SNORD50A/B deletion displayed statistically significant co-occurrence up to P = 1.1 × 10 −4 with KRAS, HRAS and NRAS mutations in multiple cancer types (Supplementary Tables 3 and 4) . Of interest, recent work found that mutational co-occurrence is more common than mutual exclusivity by identifying 148 co-occurring significantly mutated gene (SMG) combinations in comparison to 14 mutually exclusive SMGs; co-occurrence was observed between genes residing in the same signaling pathway, including the Ras and phosphoinositide 3-kinase (PI3K) pathways 22 . The co-occurrence of KRAS mutations with SNORD50A/B deletion in human cancers is consistent with our observation that SNORD50A/B deletion enhances the tumorigenesis of cells expressing oncogenic K-Ras mutants and supports the premise that mutational cooperativity occurs among genes that act within specific cancer-relevant pathways.
snoRNAs have recently been implicated in multiple processes, including neoplasia. For example, SNORA42 was found to be amplified in some non-small cell lung cancer tumors 23 . SNORD50A/B itself was previously observed to map to translocations of uncertain functional impact in B cell lymphoma 24 and to also display point mutations in a small subset of prostate tumor cell lines and tumors, although with unclear pathogenic consequences, as similar alterations were observed in germline DNA 25 . The observation here that SNORD50A and SNORD50B bind multiple GTPases may reflect a conserved class of interactions. Consistent with this possibility, in yeast, the Bms1 ribosomal GTPase protein was found to bind the yeast U3 snoRNA directly during biosynthesis of the 40S ribosomal subunit 26 . Additionally, 23S rRNA may regulate the function of ribosomal GTPases 27, 28 . In spite of the association of snoRNAs with the nucleolus, roles for them in the cytoplasm have been recently appreciated, including in metabolic stress 9 . SNORD50A and SNORD50B snoRNAs therefore represent GTPase-binding snoRNAs with effects on K-Ras regulation and tumorigenesis.
METhODS
Methods and any associated references are available in the online version of the paper. Table  Browser . Tumor sample segmented intervals that overlapped a cancer-associated gene were filtered out from analysis. Somatic CNA for each snoRNA was determined by subtracting the copy number value for the segment containing the snoRNA in the tumor sample from the copy number in the normal sample. A somatic CNA cutoff greater than an absolute value of 0.25 was used.
Survival curve analysis. Annotated clinical data for TCGA breast cancer samples were downloaded in matrix format from the UCSC Cancer Genome Browser. Additional survival data associated with SNHG5 gene expression were obtained from GEO under accession GSE6532. 'High' and 'low' values correspond to the upper and lower half of the expression values within the data set. Statistical significance was analyzed using the log-rank (Mantel-Cox) test. DNA sequencing data from somatic mutations of paired samples from TCGA were downloaded to compare the mutual exclusivity or co-occurrence of SNORD50A and SNORD50B loss with that of somatic mutation and copy number variants of cancer-associated genes. Significant co-occurrence or mutual exclusivity was determined using Fisher's exact test.
Expression analysis. Expression of the SNORD50A and SNORD50B host gene SNHG5 was determined from TCGA data for breast cancer. Expression data were analyzed using probe A_23_P361087 from the custom Agilent array. Fragments per kilobase of transcript per million mapped reads (FPKM) values for SNHG5 were used from primary melanoma cultures. Statistical significance was determined using an unpaired two-sided t test, except in the case of breast adenocarcinoma, where the samples are patient matched and a paired t test was used. Tumor-normal sample sizes were as follows: colon, 45 and 39; breast, 62 and 62; T cell lymphoma, 10 and 28; and melanoma, 2 and 2. For analysis of snoRNA host gene expression, TCGA breast invasive carcinoma gene expression data (PANCAN normalized) were downloaded from the UCSC Cancer Genome Browser (version dated 24 February 2015). Somatic gene expression changes of all snoRNA host genes with the gene prefix "SNHG" were calculated by subtracting expression values for a matched normal sample for those from a primary tumor sample in the same patient. The aggregate log 2 -tranformed gene expression changes are plotted, and only matched tumor-normal samples were included, resulting in n = 113.
Transcription factor and methylation analyses. The SNHG5 promoter region (±500 bp with respect to the transcription start site (TSS)) was overlapped with all called peaks from ENCODE ChIP-seq data, and 68 different transcription factors were identified as bound. For each of these transcription factors, the Pearson correlation was calculated between expression of the transcription factor and expression of SNHG5 in the TCGA melanoma RNA-seq data. Methylation values from the CpG island probe nearest to the SNHG5 promoter (cg10705909) were obtained from TCGA data for melanoma, correlated against SNHG5 expression in matched samples and plotted as a scatterplot. Statistical significance was determined using an unpaired two-tailed t test.
Mutational analysis of co-occurrence. All TCGA Pan-Cancer gene-level non-silent somatic mutations and TCGA Pan-Cancer gene-level copy number (GISTIC2) data were downloaded from the UCSC Cancer Genome Browser. In total, 4,224 samples with both mutation and copy number data were analyzed. Gene-level copy number alterations >0.25 (log 2 ) for KRAS, HRAS and NRAS were classified as amplifications, whereas gene-level copy number alterations <−0.25 (log 2 ) for SNHG5 were classified as deletions. Fisher's exact tests were performed between SNORD50A/B loss and RAS amplification or mutation to determine significant co-occurrence or mutual exclusivity.
Protein microarray analyses. DNA encoding SNORD50A and SNORD50B was synthesized by overlapping PCR of a construct with an SP6 promoter at the 5′ end, the resulting fragment was cloned into the pCR2.1TOPO vector (Life Technologies), and RNAs were produced and labeled with Cy5 dye with a ratio of RNA:Label IT Cy5 reagent of 1:3 and a reaction time of not more then 30 min at 37 °C to achieve between 0.5 and 1 Cy5 dye unit covalently attached to each RNA used. For RNA incubation, the ProtoArray Human Protein Microarray v5.0 (Life Technologies) was used. GO analysis and PFAM domain analysis of RNA-binding proteins were performed with BenjaminiHochberg correction of the P value. The P value for the Venn diagram illustrating overlap of two independent microarray incubations was calculated using Fisher's exact test.
snoRNA mutagenesis. pCR2.1TOPO-SNORD50A vector was used as a template for inverse PCR using oligonucleotides targeting the snoRNA C, D, C′ and D′ boxes and containing compatible infusion arms with reverse oligonucleotide.
The following mutant forms of SNORD50A were generated and used for RNA in vitro transcription and gel shifts: pCR2.1TOPO-SNORD50A′C (SNORD50A deletion of 6-12 bp), pCR2.1TOPO-SNORD50A′D (SNORD50A deletion of 69-72 bp), pCR2.1TOPO-SNORD50A′C′ (SNORD50A deletion of 35-40 bp) and pCR2.1TOPO-SNORD50A′D′ (SNORD50A deletion of 25-28 bp).
Mutant K-Ras proteins.
Deletions in the KRAS (4B) gene coding sequence were introduced by overlapping PCR amplification, and resulting sequences were cloned into the pLEX lentiviral vector containing a sequence encoding a FLAG-HA-HIS (FHH) tag in frame. For controls, wild-type KRAS coding sequence and eGFP were engineered to express the same tag and subcloned into the pLEX lentiviral vector. To match expression of delivered wild-type K-Ras protein with endogenous protein levels, the uORF-K-Ras (wild type) construct was generated containing a short upstream ORF (uORF) 5′ to the coding sequence. Using these approaches, the following constructs were generated: pLEX-FHH-K-Ras (wild type), pLEX-uORF-FHH-K-Ras (wild type), pLEX-uORF-FHH-GFP, pLEX-FHH-K-Ras′10-18 (targeting the K-Ras nucleotide-binding site), pLEX-FHH-K-Ras′28-39 (targeting the switch I region), pLEX-FHH-K-Ras′57-63 (targeting the switch II region) and pLEX-FHH-K-Ras′165-183 (targeting the C-terminal region). To predict the K-Ras residues that potentially interact with SNORD50A and SNORD50B snoRNA for point mutagenesis, the crystal structure of wild-type K-Ras (Protein Data Bank (PDB), 4LPK) was overlaid onto the crystal structure of the SRP54-SRP19 (PDB, 2V3C) 7S.S-SRP RNA complex, which contains a Ras GTPase-like domain, using PyMOL software. Site-directed mutagenesis was used to change all candidate residues to isoleucine, and the resulting sequences were cloned to generate the pLEX-FHH-K-Ras-K5I, pLEX-FHH-K-Ras-K42I, pLEX-FHH-K-Ras-R149I and pLEX-FHH-K-Ras-R161I constructs used for CLIP.
Gel-shift assays. For wild-type and mutant snoRNAs, pCR2.1TOPO vector containing snoRNAs under the control of the SP6 promoter and flanked with an SspI site at the 3′ end was used. Plasmid DNA was digested with SspI, and 4 pg of linear DNA was then in vitro transcribed in a 50-µl total volume consisting of 1× Transcription buffer (Promega), 10 mM DTT (Promega), 1 mM NTPs (Invitrogen), 40 U RNaseOUT (Invitrogen) and 60 U SP6 RNA polymerase at 37 °C for 4 h, after which DNA was digested by the addition of 2 U DNase I at 37 °C for 15 min. For gel-shift assays, 0.2 µM of the full-length or deletion-mutant forms of snoRNAs SNORD50A, SNORD50B or scrambled 74-bp (USCR) RNAs was used with the indicated amount or 0.6 µM of purified recombinant K-Ras protein (Abcam, ab96817). snoRNAs were denatured at 90 °C for 30 s in 10 µl of water, and samples were immediately transferred to ice; after adding an equal volume of 40 mM HEPES (pH 7.4) with 2 mM DTT, npg
